Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 13, 2019
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, ...
February 13, 2019
AIT Therapeutics Reports Financial Results for Fiscal Third Quarter 2019
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 13, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
February 13, 2019
Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
BASEL, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)--Urovant Sciences Ltd. (UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported ...
February 12, 2019
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
REHOVOT, Israel, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced financial results for the three and ...
February 12, 2019
Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®
ISFIYA, Israel, Feb. 12, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW), (CHEKZ), a clinical-stage medical diagnostics company advancing the development of ...
February 12, 2019
Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update
CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
February 12, 2019
Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial ...
February 12, 2019
ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 12, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
February 12, 2019
Genocea Announces Private Placement Financing of Up to $39 Million
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered ...
February 12, 2019
Fortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage ...
February 12, 2019
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public ...
February 12, 2019
OncoCyte Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early ...
February 11, 2019
Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced Submicron Surface Technology
SCHLIEREN (ZURICH), Switzerland, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private ...
February 11, 2019
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of ...
February 11, 2019
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing metabolic-based cancer therapies, today reported its financial and ...
February 11, 2019
Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina
VANCOUVER , Feb. 11, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve technologies ...
February 11, 2019
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company, today announced the completion of the first ...
February 11, 2019
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
REDWOOD CITY, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
February 11, 2019
Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced ...
February 11, 2019
AIT Therapeutics Announces Appointment of Robert F. Carey to Board of Directors
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
Page 44 of 169